CU20100143A7 - TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS - Google Patents

TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS

Info

Publication number
CU20100143A7
CU20100143A7 CU2010000143A CU20100143A CU20100143A7 CU 20100143 A7 CU20100143 A7 CU 20100143A7 CU 2010000143 A CU2010000143 A CU 2010000143A CU 20100143 A CU20100143 A CU 20100143A CU 20100143 A7 CU20100143 A7 CU 20100143A7
Authority
CU
Cuba
Prior art keywords
hormones
patch
potentiators
transdermal administration
need
Prior art date
Application number
CU2010000143A
Other languages
Spanish (es)
Other versions
CU23868B1 (en
Inventor
Stefan Bracht
Michael Dittgen
Petra Huber
Thomas Langguth
Dirk Schenk
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20100143(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CU20100143A7 publication Critical patent/CU20100143A7/en
Publication of CU23868B1 publication Critical patent/CU23868B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere a un parche que comprende una capa de droga con un bajo contenido de hormonas, como por ejemplo gestodeno, y opcionalmente un estrógeno (por ejemplo etinilestradiol). Al aplicar el parche a una mujer, se consiguen niveles en plasma de al menos 1,0 ng/ml de gestodeno en condiciones de estado estacionario sin necesidad de incorporar potenciadores de penetración ni mejoradores de permeación en la capa que contiene droga. También son satisfactorios los niveles en plasma de las hormonas que se consiguen durante todo un periodo de al menos una semana, haciendo que el parche se pueda aplicar para utilizarlo en anticoncepción femenina con el concepto de aplicar el parche una vez a la semana.The invention relates to a patch comprising a drug layer with a low content of hormones, such as, for example, signodene, and optionally an estrogen (for example ethinyl estradiol). By applying the patch to a woman, plasma levels of at least 1.0 ng / ml of signodene are achieved under steady state conditions without the need to incorporate penetration enhancers or permeation enhancers in the drug-containing layer. Plasma levels of hormones that are achieved over a period of at least one week are also satisfactory, making the patch can be applied for use in female contraception with the concept of applying the patch once a week.

CU20100143A 2003-12-12 2010-07-05 TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS CU23868B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52871803P 2003-12-12 2003-12-12
EP03078881 2003-12-12
PCT/IB2004/052752 WO2005058287A2 (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers

Publications (2)

Publication Number Publication Date
CU20100143A7 true CU20100143A7 (en) 2011-10-31
CU23868B1 CU23868B1 (en) 2013-03-27

Family

ID=34702342

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20100143A CU23868B1 (en) 2003-12-12 2010-07-05 TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS

Country Status (15)

Country Link
JP (1) JP4965263B2 (en)
KR (1) KR101168449B1 (en)
CN (1) CN1913878B (en)
AU (1) AU2004298930B2 (en)
BR (1) BRPI0417530B8 (en)
CA (1) CA2549916C (en)
CU (1) CU23868B1 (en)
EA (1) EA011160B1 (en)
EC (1) ECSP066694A (en)
IL (1) IL176112A (en)
MX (1) MXPA06006682A (en)
NO (1) NO341989B1 (en)
NZ (1) NZ548091A (en)
WO (1) WO2005058287A2 (en)
ZA (1) ZA200605713B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100704825B1 (en) 2003-02-21 2007-04-09 바이엘 쉐링 파마 악티엔게젤샤프트 ＵＶ Stability Transdermal Therapy Plaster
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (en) * 2005-10-19 2007-04-26 Schering Ag Method of preventive on-demand hormonal contraception
FR2900048B1 (en) * 2006-04-21 2012-11-16 Oreal COMPOSITIONS COMPRISING A DIPHENYL-METHANE HYDROXYLATED DERIVATIVE
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
DE102010040299A1 (en) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
WO2012031999A2 (en) 2010-09-06 2012-03-15 Bayer Pharma Aktiengesellschaft Low-dose transdermal patches with high drug release
EP2806862A2 (en) * 2012-01-27 2014-12-03 Agile Therapeutics, Inc. Transdermal hormone delivery
HK1251938A1 (en) * 2015-05-18 2019-05-03 敏捷治疗公司 Contraceptive compositions and methods for improved efficacy and modulation of side effects

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394429B1 (en) * 1988-10-27 1996-01-10 Schering Aktiengesellschaft Preparation for transdermal application containing gestodene
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
NZ240358A (en) * 1990-10-29 1994-09-27 Alza Corp Transdermal contraceptive device comprising (as active agents) an estrogen and a gestodene together with a skin permeation enhancer
DE4329242A1 (en) * 1993-08-26 1995-03-02 Schering Ag Agent for transdermal application containing gestodenester
DE4405898A1 (en) * 1994-02-18 1995-08-24 Schering Ag Transdermal therapeutic systems containing sex steroids
KR970706805A (en) * 1994-11-18 1997-12-01 나까토미 히로타카 Percutaneous Absorption Patch (PERCUTANEOUSLY ABSORBABLE PATCH)
CN1188189C (en) * 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with estrogen
JP4346696B2 (en) * 1996-05-28 2009-10-21 久光製薬株式会社 Transdermal therapeutic device
JP4167750B2 (en) * 1997-04-16 2008-10-22 久光製薬株式会社 Transdermal absorption base and percutaneous absorption preparation containing the base
JP4399044B2 (en) * 1998-10-14 2010-01-13 久光製薬株式会社 Absorption enhancer and transdermal absorption preparation comprising the absorption enhancer
DE19906152B4 (en) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Active substance-containing laminates for transdermal systems
WO2001001990A1 (en) * 1999-07-01 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Adhesive preparation for percutaneous absorption
DE10053375C1 (en) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermal therapeutic system with light-sensitive agent in polymer matrix and backing, useful for therapy with e.g. nicotine, nifedipine, lacidipine, gestagen, vitamin B 12 or antibiotic, contains colorless ultraviolet absorber
AU2002235155A1 (en) * 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems

Also Published As

Publication number Publication date
CN1913878A (en) 2007-02-14
EA011160B1 (en) 2009-02-27
NO341989B1 (en) 2018-03-12
CA2549916C (en) 2013-09-17
KR20060128910A (en) 2006-12-14
BRPI0417530B8 (en) 2021-05-25
JP2007513938A (en) 2007-05-31
NO20062594L (en) 2006-07-10
EA200601089A1 (en) 2006-12-29
ECSP066694A (en) 2006-10-31
IL176112A0 (en) 2006-10-05
CA2549916A1 (en) 2005-06-30
AU2004298930B2 (en) 2009-11-26
CN1913878B (en) 2010-05-26
CU23868B1 (en) 2013-03-27
MXPA06006682A (en) 2006-08-11
KR101168449B1 (en) 2012-07-25
AU2004298930A1 (en) 2005-06-30
WO2005058287A2 (en) 2005-06-30
JP4965263B2 (en) 2012-07-04
IL176112A (en) 2011-02-28
ZA200605713B (en) 2008-01-08
NZ548091A (en) 2009-12-24
BRPI0417530A (en) 2007-03-13
WO2005058287A3 (en) 2006-03-02
BRPI0417530B1 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
CU20100143A7 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
CY1115064T1 (en) HYDRAULIC INTERDERATIVE HYMN TRADE SYSTEM WITHOUT LEADING AID
NO993520L (en) Dosage forms and methods for better erectile dysfunction
ATE329586T1 (en) COMPOSITIONS CONTAINING CAROTENOIDS AND THEIR USE FOR PREVENTING HORMONE-INDUCED SIDE EFFECTS
ES2190472T3 (en) TRANSDERMIC PATCH FOR THE ADMINISTRATION OF 17-DEACETIL NORGESTIMATO, ONLY OR IN COMBINATION WITH A STROGEN.
BR0312007A (en) Transcutaneous administration rate control using amorphous pharmaceutical compositions
CR7610A (en) USE OF THIO-OXINDOL DERIVATIVES IN THE TREATMENT OF CONDITIONS MADE WITH HORMONE
MXPA04005211A (en) Transdermal therapeutic systems containing steroid hormones and propylene glycol monocaprylate.
MX2022008277A (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof.
ATE382356T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ESTETROL DERIVATIVES AND USE IN CANCER TREATMENT
CU23264B7 (en) PREPARED DELAYED RELEASE OF ANTIBIOTICS OF QUINOLONA AND PROCEDURE FOR PREPARATION
AR021459A1 (en) PATCH CONTAINING ESTRADIOL FOR THE PERCUTANEOUS APPLICATION OF HORMONES.
UY28668A1 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
AR049197A1 (en) HORMONAL CONTRACEPTIVE CONTAINING A COMBINATION OF ETHYLINESTRADIOL AND CLORMADINONE ACETATE
CU20060121A7 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
CR8059A (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF HYDROGEL FOR TRANSDERMAL ADMINISTRATION OF ACTIVE SUBSTANCES
TR200601092T1 (en) New oral pharmaceutical formulations containing the active ingredient irbesartan.
PE20070119A1 (en) NEW REGIMES FOR CONTROLLED DELIVERY DEVICES FOR CONTRACEPTION DRUGS
ATE269063T1 (en) FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF FENOLDOPAM
PL359235A1 (en) Therapeutic agent

Legal Events

Date Code Title Description
FG Grant of patent